The Innovation Firm

When

August 8, 2018
11:30 AM - 1:30 PM

Where

UConn Health Technology Incubation Program Building Grossman Auditorium
400 Farmington Avenue
Farmington, CT 06032

Successful Commercialization of your Innovation

Mark Solomon and Deirdre Sanders presented "Successful Commercialization of your Innovation" on August 8, 2018, at the UConn Technology Incubation Program in Farmington, CT.  Aaron Schwartz, Director of Search & Evaluation Global Drug Discovery from Novo Nordisk and tech transfer experts from UConn also participated in this seminar.  The presentation covered topics to increase your understanding of what industry wants and the patent system requires to position your innovation for successful commercialization.  UConn’s Technology Commercialization Directors described their role in facilitating that success.

Key topics:

  • What timing issues should I consider after I recognize my innovation?
  • What are the first steps I should take to avoid accidental pitfalls?
  • What details should I develop and describe to increase the likelihood of obtaining an enforceable, valid patent?
  • What data should I provide to maximize the commercial value of my innovation?
  • When should I speak to potential partners?
  • How much information should I share with potential partners?
  • What is my time commitment during the licensing process and the patenting process?

The presentation was followed by Q & A and a networking lunch in the Cafe.

Click here to register.

 

Deirdre E. Sanders
Principal Attorney, Life Sciences
Hamilton Brook Smith Reynolds

Deirdre has 20+ years of experience in strategic biotechnology patent prosecution counseling and in intellectual property litigation and enforcement.  She is dedicated to guiding clients through the development, management, and protection of intellectual property rights to achieve their business goals. Deirdre’s patent practice is focused in the field of biotechnology with a particular emphasis in the areas of biologics including antibody-based therapeutics, pharmaceuticals, immuno-oncology and immunotherapy, vaccines, microbiomes, bioinformatics, protein-based sensors, and drug discovery and development.

 

Mark B. Solomon
Principal Attorney, Engineering
Hamilton Brook Smith Reynolds

Mark’s 20 years in patent law complements his 10 years as an electrical and control systems engineer, which he uses in guiding companies and universities through the development, management, protection, and enforcement of intellectual property rights. He provides high value IP services for clients who value IP by drafting and prosecuting patent applications from strategic business or licensing perspectives. Mark’s technical background includes diverse engineering technologies, such as motion control systems, process control systems, medical devices, mechanical devices, robotics, autonomous vehicles, telecommunications, optics and opto-electronics, signal processing, image processing, voice processing, optical networking and electrical networking, business methods, analog electronics and digital electronics, software, GPS systems, antennas, mobile devices, nano-materials, semiconductors, fuel cells and other renewable energy systems, artificial intelligence such as neural networks, and the Internet-of-Things.

 

Aaron Schwartz
Director, Search & Evaluation, Global Drug Discovery
Novo Nordisk

Aaron has been a Director in Novo Nordisk’s Search & Evaluation team in Global Drug Discovery  since 2016.  In this capacity, Aaron is responsible for the search and evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs.  Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years.  During this time, he worked on license and sponsored research agreements with life sciences companies from startups to big biotech/pharma and everything in between.  He also managed a portfolio of over 650 technologies.  Before Aaron’s time at MIT, he was a management consultant to big pharma and a startup.  Aaron has an undergraduate degree in biology from the University of Chicago and a Masters degree in biology from MIT.

Overview

When

August 8, 2018
11:30 AM - 1:30 PM

Where

UConn Health Technology Incubation Program Building Grossman Auditorium
400 Farmington Avenue
Farmington, CT 06032

Mark Solomon and Deirdre Sanders presented "Successful Commercialization of your Innovation" on August 8, 2018, at the UConn Technology Incubation Program in Farmington, CT.  Aaron Schwartz, Director of Search & Evaluation Global Drug Discovery from Novo Nordisk and tech transfer experts from UConn also participated in this seminar.  The presentation covered topics to increase your understanding of what industry wants and the patent system requires to position your innovation for successful commercialization.  UConn’s Technology Commercialization Directors described their role in facilitating that success.

Key topics:

  • What timing issues should I consider after I recognize my innovation?
  • What are the first steps I should take to avoid accidental pitfalls?
  • What details should I develop and describe to increase the likelihood of obtaining an enforceable, valid patent?
  • What data should I provide to maximize the commercial value of my innovation?
  • When should I speak to potential partners?
  • How much information should I share with potential partners?
  • What is my time commitment during the licensing process and the patenting process?

The presentation was followed by Q & A and a networking lunch in the Cafe.

Click here to register.

 

Presenter Bios

Deirdre E. Sanders
Principal Attorney, Life Sciences
Hamilton Brook Smith Reynolds

Deirdre has 20+ years of experience in strategic biotechnology patent prosecution counseling and in intellectual property litigation and enforcement.  She is dedicated to guiding clients through the development, management, and protection of intellectual property rights to achieve their business goals. Deirdre’s patent practice is focused in the field of biotechnology with a particular emphasis in the areas of biologics including antibody-based therapeutics, pharmaceuticals, immuno-oncology and immunotherapy, vaccines, microbiomes, bioinformatics, protein-based sensors, and drug discovery and development.

 

Mark B. Solomon
Principal Attorney, Engineering
Hamilton Brook Smith Reynolds

Mark’s 20 years in patent law complements his 10 years as an electrical and control systems engineer, which he uses in guiding companies and universities through the development, management, protection, and enforcement of intellectual property rights. He provides high value IP services for clients who value IP by drafting and prosecuting patent applications from strategic business or licensing perspectives. Mark’s technical background includes diverse engineering technologies, such as motion control systems, process control systems, medical devices, mechanical devices, robotics, autonomous vehicles, telecommunications, optics and opto-electronics, signal processing, image processing, voice processing, optical networking and electrical networking, business methods, analog electronics and digital electronics, software, GPS systems, antennas, mobile devices, nano-materials, semiconductors, fuel cells and other renewable energy systems, artificial intelligence such as neural networks, and the Internet-of-Things.

 

Aaron Schwartz
Director, Search & Evaluation, Global Drug Discovery
Novo Nordisk

Aaron has been a Director in Novo Nordisk’s Search & Evaluation team in Global Drug Discovery  since 2016.  In this capacity, Aaron is responsible for the search and evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs.  Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years.  During this time, he worked on license and sponsored research agreements with life sciences companies from startups to big biotech/pharma and everything in between.  He also managed a portfolio of over 650 technologies.  Before Aaron’s time at MIT, he was a management consultant to big pharma and a startup.  Aaron has an undergraduate degree in biology from the University of Chicago and a Masters degree in biology from MIT.

Back to the Top